The Cardiovascular Comorbidity in Children With Chronic Kidney Disease Study (4C)

January 11, 2010 updated by: Heidelberg University

The Cardiovascular Morbidity in Children With Chronic Renal Failure Study

Children and adolescents with chronic kidney disease (CKD) are at high risk for cardiovascular (CV) morbidity and mortality. Recent studies suggest that pediatric patients with even moderately impaired kidney function may be afflicted with significant early cardiac and vascular abnormalities.

The pathogenesis and the natural course of CV comorbidity in pediatric CKD patients is still elusive. In this multicenter, prospective, observational study the prevalence, degree and progression of CV comorbidity in children will be characterized and related to CKD progression. The morphology and function of the heart and vessels will be monitored by sensitive, non-invasive methods and will be compared with aged matched healthy controls. Multiple potential clinical, anthropometric, biochemical, and pharmacological risk factors will be monitored prospectively and will be related to CV status. Genotyping might identify predisposing genetic factors for progression of CV comorbidity and underlying nephropathies.

Study Overview

Detailed Description

Adult patients with CKD are at markedly increased risk of dying from cardiovascular events. The risk is most dramatically increased in young patients with end-stage renal disease, who are almost as likely to die from cardiovascular causes as elderly individuals in the general population.

Early morphological and functional vascular abnormalities can be detected even in adolescents with CKD, but information about the prevalence, severity and natural course of vascular lesions in different stages of renal failure is lacking and the factors predisposing to an early onset and rapid progression of cardiovascular morbidity are still elusive.

The pediatric population appears uniquely suited to study the effects of CKD on the cardiovascular system due to the virtual absence of vascular morbidity related to ageing, diabetes and smoking.

In order to improve our understanding of the causes and consequences of cardiovascular comorbidity in children with progressive CKD, a consortium of pediatric nephrologists in Europe has joined to perform a long-term prospective observational study following the cardiovascular health of children as they advance through successive stages of CKD.

The 4C Study will follow up at least 625 patients aged 6 to 17 years with a glomerular filtration rate of 10 to 45 ml/min/1.73 m² in more than 40 pediatric nephrology units in 14 European countries.

The morphology and function of the heart and the large arteries is regularly assessed by sensitive, non-invasive methods and the findings compared to a large group of healthy children.

Multiple potential clinical, anthropometric, biochemical, and pharmacological risk factors are monitored prospectively and will be related to the cardiovascular status of the patients.

A whole genome association study will be performed to identify genetic variants associated with the progression of cardio-vascular alterations and renal failure.

Study Type

Observational

Enrollment (Anticipated)

650

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Vienna, Austria, 1010
      • Gent, Belgium, 9000
      • Prague, Czech Republic, 15006
        • Not yet recruiting
        • University Hospital Motol
        • Contact:
      • Lyon, France, 69677
        • Not yet recruiting
        • Service de Pédiatrie & Inserm U820
        • Contact:
      • Strasbourg, France, 67098
      • Berlin, Germany, 13353
        • Not yet recruiting
        • Charité Children's Hospital
        • Contact:
        • Contact:
        • Sub-Investigator:
          • René Zeller, MD
      • Cologne, Germany, 50937
      • Erlangen, Germany, 91054
      • Essen, Germany, 45122
        • Not yet recruiting
        • University Children's Hospital
        • Contact:
      • Freiburg, Germany, 79106
      • Hamburg, Germany, 20246
        • Not yet recruiting
        • UKE University Children's Hospital
        • Contact:
      • Hannover, Germany, 30625
      • Heidelberg, Germany, 69120
      • Leipzig, Germany, 04129
      • Marburg, Germany, 35043
        • Not yet recruiting
        • KfH Kidney Center for Children
        • Contact:
      • Münster, Germany, 48149
      • Rostock, Germany, 18057
      • Budapest, Hungary, 1083
        • Not yet recruiting
        • Semmelweis University
        • Contact:
      • Bologna, Italy, 40123
        • Not yet recruiting
        • S. Orsola-Malphighi Hospital
        • Contact:
      • Genova, Italy, 16147
      • Milano, Italy, 20122
        • Not yet recruiting
        • Fondazione OSP Maggiore Policlinico
        • Contact:
      • Padova, Italy, 35128
        • Not yet recruiting
        • University of Padova
        • Contact:
      • Rome, Italy, 00163
        • Not yet recruiting
        • Bambino Gesu
        • Contact:
      • Torino, Italy, 10126
        • Not yet recruiting
        • Regina Margherita Children's Hospital
        • Contact:
      • Vilnius, Lithuania, 08406
        • Not yet recruiting
        • Vilnius University Children's Hospital
        • Contact:
      • Gdansk, Poland, 80211
        • Not yet recruiting
        • Medical University Gdansk
        • Contact:
          • Aleksandra Zurowska, MD
          • Phone Number: +48 601919335
          • Email: azur@amq.qda.pl
      • Krakow, Poland, 30-663
        • Not yet recruiting
        • University Children's Hospital
        • Contact:
      • Szczecin, Poland, 71-344
        • Not yet recruiting
        • Clinic of Pediatrics
      • Warsaw, Poland, 04-730
        • Not yet recruiting
        • Children's Memorial Health Institute
        • Contact:
          • Mieczyslaw Litwin, MD
          • Phone Number: +48 228151603
          • Email: m.liwin@czd.pl
        • Contact:
        • Sub-Investigator:
          • Mieczyslaw Litwin, MD
      • Porto, Portugal, 4200
      • Belgrade, Serbia, 11000
        • Not yet recruiting
        • University Children's Hospital
        • Contact:
      • Stockholm, Sweden, 14186
        • Not yet recruiting
        • Karolinska University Hospital
        • Contact:
      • Bern, Switzerland, 3010
      • Zurich, Switzerland, 8032
        • Not yet recruiting
        • University Children's Hospital
        • Contact:
      • Adana, Turkey, 01330
        • Recruiting
        • Çukurova Üniversitesi
        • Contact:
        • Contact:
        • Sub-Investigator:
          • Aysun Bayazit, MD
      • Ankara, Turkey, 06100
        • Not yet recruiting
        • Ankara University of Medicine
        • Contact:
      • Ankara, Turkey, 06100
        • Not yet recruiting
        • Hacettepe Medical Faculty
        • Contact:
          • Ali Duzova, MD
          • Phone Number: +90 3123051863
        • Contact:
        • Sub-Investigator:
          • Ali Duzova, MD
      • Ankara, Turkey, 06500
        • Not yet recruiting
        • Gazi University Hospital
        • Contact:
      • Ankara, Turkey
        • Not yet recruiting
        • Baskent University, Faculty of Medicine
        • Contact:
      • Ankara, Turkey
      • Ankara, Turkey
      • Istanbul, Turkey, 34303
        • Recruiting
        • Cerrahpasa Tip Fakultesi
        • Contact:
      • Istanbul, Turkey, 34360
        • Not yet recruiting
        • Istanbul Medical Faculty
        • Contact:
      • Istanbul, Turkey
        • Not yet recruiting
        • Bakirkoy Children's Hospital
        • Contact:
      • Istanbul, Turkey
        • Not yet recruiting
        • Goztepe Educational and Research Hospital
        • Contact:
      • Istanbul, Turkey
        • Not yet recruiting
        • Haseki Educational and Research Hospital
        • Contact:
        • Sub-Investigator:
          • Mahmut Civilibal, MD
      • Istanbul, Turkey
        • Not yet recruiting
        • Marmara University Medical Faculty
        • Contact:
      • Istanbul, Turkey
        • Not yet recruiting
        • Sisli Educational and Research Hospital
        • Contact:
      • Izmir, Turkey, 35100
        • Not yet recruiting
        • Ege University
        • Contact:
        • Contact:
        • Sub-Investigator:
          • Betül Sözeri, MD
      • London, United Kingdom, WC1N3JH
        • Not yet recruiting
        • Great Ormond Street Hospital
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

6 years to 17 years (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

650 children with CKD stage IIIb to V (GFR 10-45 ml/min/1.73m²). Children who reach end-stage renal disease will be continuously followed while on renal replacement therapy.

Description

Inclusion Criteria:

  • Age 6 to 17 years
  • GFR 10 to 45 ml/min/1.73m² (CKD stage IIIb to V);

Exclusion Criteria:

  • Active systemic vasculitis
  • Diabetes mellitus
  • Renal vascular anomalies
  • Anomalies of the limbs preventing standardized diagnostic procedures

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
4C
Children with chronic kidney disease stage IIIb to V (GFR 10 to 45 ml/min/1.73m²) at screening.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Functional and morphological evidence of cardiovascular disease progression (arterial stiffness, myocardial dysfunction, cIMT, LVMI) and association with clinical, anamnestic, anthropometric, biochemical, drug-related and genetic risk factors
Time Frame: 3 years
3 years

Secondary Outcome Measures

Outcome Measure
Time Frame
Genetic risk factors for early manifesting progressive vascular lesions and progressive kidney disease by the genome-wide SNP-screening and haplotype analysis.
Time Frame: 3 years
3 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Franz Schaefer, MD, Center for Pediatric and Adolescent Medicine, University of Heidelberg, Germany
  • Principal Investigator: Uwe Querfeld, MD, Klinik für Pädiatrie m.S. Nephrologie, Charite, 13353 Berlin, Germany

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

July 1, 2009

Primary Completion (Anticipated)

April 1, 2014

Study Completion (Anticipated)

April 1, 2014

Study Registration Dates

First Submitted

August 7, 2009

First Submitted That Met QC Criteria

January 11, 2010

First Posted (Estimate)

January 12, 2010

Study Record Updates

Last Update Posted (Estimate)

January 12, 2010

Last Update Submitted That Met QC Criteria

January 11, 2010

Last Verified

January 1, 2010

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cardiovascular Disease

Subscribe